

26thEAHPCONGRESS23-25MARCH

Vieldina 2022 hospital pharmacists changing roles in a changing world

EAHP thanks the continued support of its Partners

QUALITY OF LIFE STUDY: GALCANEZUMAB IN THE TREATMENT OF MIGRAINE

E.M. BARREIRO FERNANDEZ¹, E. RIOS- SANCHEZ¹, C.M. DOMINGUEZ-SANTANA¹, C. MORENO-RAMOS¹, M.D. GIL-SIERRA¹. ¹HOSPITAL UNIVERSITARIO PUERTO REAL, SERVICIO DE FARMACIA, CADIZ, SPAIN

Background and importance

Galcanezumab is a monoclonal antibody used for migraine prevention. Its approval was based on demonstrated efficacy through reduction of migraine days and impact on quality of life. However, this last variable isn't routinely monitored in real practice.

>Aim and objectives

To determine the improvement of the quality of life the patients with migraine in treatment with galcanezumab and correlated with effectiveness in real practice.

Material and methods

STUDY DESIGN


• Prospective study

Questionnaire version 2.1(MSQ)

• February 2020 to September 2021

QUALITY OF LIFE





Conclusion and relevance

1.After 12 weeks, only 17% patients obtained response for RR domain; and even, 1 of 4 patients worsening quality of life.

2. Effectiveness obtained in few patients be correlated with quality of life. Therefore, quality of life questionaries should be one more tool to evaluate treatment effectiveness. 4CPS-064